Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
Primary amine groups on proteins and extracellular matrix (ECM) components, specifically the N-terminal alpha-amino group and the epsilon-amino group of lysine residues, are fundamental chemical moieties in biological systems (Hermanson, G. T., Bioconjugate Techniques, 2013). These groups are highly nucleophilic, making them primary sites for post-translational modifications such as acetylation, methylation, and ubiquitination, which regulate protein function and degradation (UniProt). In the extracellular matrix, these amines are essential for the formation of covalent cross-links, mediated by enzymes like lysyl oxidase, which provide structural integrity to tissues (NCBI, PMC3494131). Pathologically, these groups are the site of non-enzymatic glycation by reducing sugars, leading to the accumulation of advanced glycation end-products (AGEs) associated with diabetes and vascular complications (PubMed, PMID: 15356213). From a pharmacological perspective, they are targeted by chemical cross-linkers like glutaraldehyde to stabilize bioprosthetic heart valves or by PEGylation reagents to enhance the half-life of therapeutic proteins (PubChem). However, because these amines are ubiquitous, they are generally considered a broad chemical class rather than a specific therapeutic target, presenting significant challenges for selective drug delivery. Consequently, they are more often viewed as reactive handles for chemical biology and materials science rather than traditional drug targets for systemic administration.
Drugs or reagents typically react with the nucleophilic nitrogen of the primary amine to form covalent bonds, such as Schiff bases, amides, or secondary/tertiary amines, leading to cross-linking or modification of the protein's physical and chemical properties (Hermanson, G. T., Bioconjugate Techniques, 2013).
4 more in the full profile.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Primary amine groups on proteins and extracellular matrix components.